Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$297.70 +0.4%	$293.30	$253.30 ▼ $339.17	$159.67B	0.49	2.86 million shs	331,154 shs
BIIB Biogen	$140.65 +1.5%	$130.13	$110.04 ▼ $207.59	$20.49B	0.13	1.55 million shs	27,158 shs
GILD Gilead Sciences	$119.35 +0.8%	$111.88	$73.27 ▼ $121.83	$147.44B	0.33	8.31 million shs	27,905 shs
MRNA Moderna	$28.31 +1.0%	$29.20	$23.15 ▼ $91.99	$11.01B	1.83	10.73 million shs	124,324 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	+2.86%	+0.58%	+7.48%	-7.77%
BIIB Biogen	0.00%	+6.07%	+10.89%	+7.08%	-31.36%
GILD Gilead Sciences	0.00%	-0.87%	+9.38%	+11.50%	+60.44%
MRNA Moderna	0.00%	+7.27%	-10.36%	+6.18%	-67.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.663 of 5 stars	2.2	4.0	3.3	3.9	2.9	2.5	1.9
BIIB Biogen	4.8617 of 5 stars	4.2	3.0	0.0	3.7	3.9	2.5	1.9
GILD Gilead Sciences	4.8453 of 5 stars	1.4	5.0	4.2	4.1	2.9	2.5	3.1
MRNA Moderna	4.5531 of 5 stars	4.0	2.0	0.0	4.6	1.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.33	Hold	$303.76	2.03% Upside
BIIB Biogen	2.34	Hold	$185.74	32.06% Upside
GILD Gilead Sciences	2.80	Moderate Buy	$114.82	-3.80% Downside
MRNA Moderna	2.04	Hold	$43.59	53.99% Upside

Current Analyst Ratings Breakdown

Latest GILD, BIIB, AMGN, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00 ➝ $118.00
8/8/2025	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$96.00 ➝ $98.00
8/8/2025	GILD Gilead Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$108.00 ➝ $112.00
8/8/2025	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $127.00
8/6/2025	AMGN Amgen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$305.00 ➝ $310.00
8/6/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$330.00 ➝ $333.00
8/6/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$326.00 ➝ $317.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.80	$30.50 per share	9.76	$10.93 per share	27.24
BIIB Biogen	$9.68B	2.13	$23.44 per share	6.00	$114.71 per share	1.23
GILD Gilead Sciences	$28.75B	5.15	$6.93 per share	17.23	$15.44 per share	7.73
MRNA Moderna	$3.24B	3.40	N/A	N/A	$28.33 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$12.23	24.25	13.92	2.55	18.96%	174.71%	13.12%	10/29/2025 (Estimated)
BIIB Biogen	$1.63B	$10.46	13.36	8.52	1.09	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
GILD Gilead Sciences	$480M	$5.02	23.67	14.72	0.73	21.86%	50.99%	17.24%	11/5/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)

Latest GILD, BIIB, AMGN, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.20%	N/A	77.84%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.65%	N/A	62.95%	10 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest GILD, BIIB, AMGN, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	GILD Gilead Sciences	quarterly	$0.79	2.7%	9/15/2025	9/15/2025	9/29/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	7.24	1.31	0.98
BIIB Biogen	0.36	2.50	1.79
GILD Gilead Sciences	1.13	1.32	1.15
MRNA Moderna	N/A	3.93	3.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BIIB Biogen	0.18%
GILD Gilead Sciences	0.27%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	538.36 million	534.65 million	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable

GILD, BIIB, AMGN, and MRNA Headlines

Recent News About These Companies

Moderna (NASDAQ:MRNA) Stock Price Up 6.6% - Time to Buy?

August 17 at 3:00 PM | marketbeat.com

If You're in Your 30s, Consider Buying These 2 Healthcare Stocks

August 17 at 9:30 AM | fool.com

Neuberger Berman Group LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

August 17 at 5:32 AM | marketbeat.com

Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA)

August 17 at 2:19 AM | marketbeat.com

Invesco Ltd. Grows Holdings in Moderna, Inc. (NASDAQ:MRNA)

August 16 at 4:18 AM | marketbeat.com

UK Court of Appeal Upholds Moderna mRNA Patent Against Pfizer/BioNTech

August 16 at 2:21 AM | jdsupra.com

RFK Jr.’s mRNA hostility could hurt more than just vaccines

August 15 at 8:20 PM | bostonglobe.comB

Scientists: mRNA Vaccine Research Cuts Undermine U.S. Innovation

August 15 at 4:50 AM | insidehighered.comI

RFK risks us all in targeting mRNA vaccine research

August 15 at 4:50 AM | grandhaventribune.comG

Moderna, Inc. (NASDAQ:MRNA) Stake Raised by Charles Schwab Investment Management Inc.

August 15 at 3:42 AM | marketbeat.com

RFK Jr. Creates More Vaccine Misinformation With mRNA Cancellations

August 14, 2025 | biospace.comB

Blair William & Co. IL Has $289,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

August 14, 2025 | marketbeat.com

Saving lives no more: RFK risks us all in targeting mRNA vaccine research

August 13, 2025 | nydailynews.com

How the Trump administration spoke about mRNA shots in 1st term versus 2nd term

August 13, 2025 | msn.com

Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA

August 13, 2025 | msn.com

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Deutsche Bank AG

August 13, 2025 | marketbeat.com

Trump previously called mRNA vaccines a 'medical miracle.' Now, RFK Jr. cut $500M in funding

August 12, 2025 | msn.com

How federal cuts to mRNA vaccine development will affect Vermont

August 12, 2025 | vtdigger.orgV

NIH director: mRNA vaccine contracts were canceled because public lacks trust in technology

August 12, 2025 | statnews.comS

Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

August 12, 2025 | marketbeat.com

Vanguard Group Inc. Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD, BIIB, AMGN, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

$297.70 +1.23 (+0.42%)

As of 09:49 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$140.65 +2.05 (+1.48%)

As of 09:49 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$119.35 +0.98 (+0.83%)

As of 09:49 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$28.30 +0.29 (+1.02%)

As of 09:49 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time